MedTrace Logo

Rh-Endostatin (Endostar®) Continuous Intravenous Infusion

NCT03706703 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-10-17

No results posted yet for this study

Summary

Endostar is a anti-angiogenesis product and has been launched in China . The efficacy and safety have been defined. However, the compliance is unsatisfactory since routine i.v of Endostar is needed for 3 to 4 hours daily during one cycle of 14 days. The continuous intravenous infusion by using venous pump can improve the compliance.

Conditions

Interventions

DRUG

Endostar

continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.

DRUG

Docetaxel

docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle

DRUG

Carboplatin

carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed

DRUG

Pemetrexed

pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle

Sponsors & Collaborators

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-04-01
Completion
2020-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706703 on ClinicalTrials.gov